Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-MEK2 Antibody (8K565) is a Mouse antibody targeting MEK2. Anti-MEK2 Antibody (8K565) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-MEK2 Antibody (8K565) is a Mouse antibody targeting MEK2. Anti-MEK2 Antibody (8K565) can be used in ELISA. |
Alias | PRKMK2, MKK2, mitogen-activated protein kinase kinase 2, MEK2, MAPKK2, FLJ26075, CFC4 |
Ig Type | Monoclonal Mouse IgG2b |
Clone | 8K565 |
Reactivity | Human |
Application | ELISA |
Recommended Dose | ELISA: 1:1000-1:2000 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human MEK2/MAP2K2/MKK2 (rh MEK2/MAP2K2/MKK2; TMPY-04544; NP_109587.1; Met1-Val400). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains one protein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 / MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 / MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of Cardiofaciocutaneous Syndrome (CFC Syndrome) which is characterized by a distinctive facial appearance, heart defects, and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects, and hypertrophic cardiomyopathy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Immunogen | Recombinant Human MEK2/MAP2K2/MKK2 Protein (TMPY-04544) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.